Betalactam can treat atrial fibrillation and is the drug of choice for ventricular rate control in the treatment of atrial fibrillation. In most patients with atrial fibrillation who are treated clinically with a ventricular rate control strategy, the patient will take betalac for a long time to control the patient’s ventricular rate in atrial fibrillation as long as there are no contraindications. In addition to ventricular rate control in AF, oral anticoagulants are also given long-term for anticoagulation to prevent peripheral arterial embolism, especially cerebral embolism. Betalactam is a selective β1 receptor blocker that slows the heart rate, reduces myocardial contractility, and decreases sympathetic excitability. In persistent atrial fibrillation, the prognosis is not significantly different from that of patients who maintain sinus rhythm after cardioversion, especially in elderly patients, when betalactam is chosen to control the ventricular rate and prevent thromboembolism.